Samir Parekh, MBBS
img_Samir Parekh
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Oncological Sciences
Are you a patient?
Hematology-Oncology, Cancer (Oncology)
Research Topics
Computational Biology, Drug Resistance, Epigenetics, Lymphoma, Transcriptional Activation and Repression
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Mantle Cell Lymphoma (MCL)
MCL is a rare and incurable non-Hodgkins lymphoma whose pathogenesis is not clearly understood. The SOX11 transcription factor is overexpressed in the majority of Mantle cell lymphomas. We identified the direct DNA binding targets of SOX11 in several oncogenic pathways using ChIP-sequencing and functional genomics and have now developed an inducible mouse model of SOX11 overexpression that recapitulates the MCL phenotype. We are developing anti-SOX11 small molecules with structural biologist Dr. Aneel Aggarwal at Mount Sinai that could be applicable in MCL and other SOX11 expressing tumors like lung cancer, ovarian cancer and glioma.

Visit the Parekh Laboratory

Integrative Genomics for Drug repositioning in Myeloma
With the advent of next-generation sequencing, we have been systematically developing and studying the application of integrative genomics (including methylation, gene expression and exome sequencing) to guide personalized repurposing of FDA approved drugs to overcome chemotherapy resistance in B cell malignancies like non-Hodgkins Lymphoma and Multiple Myeloma. I have an ongoing IRB approved clinical trial for genomic signature guided therapeutic selection in collaboration with Drs. Jagannath and Schadt, Dean for Precision Medicine and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.

MBBS, KJ Somaiya Medical College

Residency, Internal Medicine, John H Stroger Jr Hospital of Cook County

Fellowship, Hematology & Oncology, Montefiore/Albert Einstein College of Medicine Rheumatology


American Board of Internal Medicine


Young Investigator Award


Young Investigator Travel Award


First Overall and Highest Rank in General Internal Medicine

K.J. Somaiya Medical College

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Parekh during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Genentech, Inc.
  • GRAIL, Inc

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.